Tempest Therapeutics

Contributing Author

Recent Articles by Tempest Therapeutics

12 hours	Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T TPST GlobeNewswire
Apr-14	Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts TPST +5.14% GlobeNewswire
Mar-30	Tempest Reports Year End 2025 Financial Results and Provides Business Update TPST -12.14% GlobeNewswire
Mar-23	Tempest Therapeutics Announces Up To $6 Million Private Placement TPST -19.65% GlobeNewswire
Mar-11	Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 TPST GlobeNewswire
Feb-25	Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 TPST -6.43% GlobeNewswire
Feb-11	Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets TPST GlobeNewswire
Feb-04	Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets TPST -6.30% TPST GlobeNewswire
Jan-20	Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders TPST -5.15% GlobeNewswire
Nov-26	Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules TPST GlobeNewswire
Nov-25	Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules TPST -23.26% GlobeNewswire
Nov-19	Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 TPST -48.59% GlobeNewswire
Nov-05	Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update TPST +9.10% GlobeNewswire
Aug-11	Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update TPST +9.99% TPST +8.83% GlobeNewswire
Jun-30	Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China TPST GlobeNewswire
Jun-11	Tempest Announces $4.6 Million Registered Direct Offering of Common Stock TPST -15.88% GlobeNewswire
Jun-05	Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC TPST +15.16% GlobeNewswire
May-13	Tempest Reports First Quarter 2025 Financial Results and Provides Business Update TPST GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)